AACR logo

More articles from Large Molecule Therapeutics

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo
Rocio Montes de Oca, Alireza S. Alavi, Nick Vitali, Sabyasachi Bhattacharya, Christina Blackwell, Krupa Patel, Laura Seestaller-Wehr, Heather Kaczynski, Hong Shi, Eric Dobrzynski, Leslie Obert, Lyuben Tsvetkov, David C. Cooper, Heather Jackson, Paul Bojczuk, Sabrina Forveille, Oliver Kepp, Allan Sauvat, Guido Kroemer, Mark Creighton-Gutteridge, Jingsong Yang, Chris Hopson, Niranjan Yanamandra, Christopher Shelton, Patrick Mayes, Joanna Opalinska, Mary Barnette, Roopa Srinivasan, James Smothers, Axel Hoos

Molecular Cancer Therapeutics Oct 2021, 20 (10) 1941-1955; DOI: 10.1158/1535-7163.MCT-21-0035
Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule
Elizabeth Pham, Matthias Friedrich, Famke Aeffner, Michael Lutteropp, Natalie F. Mariano, Petra Deegen, Christoph Dahlhoff, Franziska Vogel, Claudia Bluemel, John M. Harrold, Christian Brandl, Natalia Grinberg, Benno Rattel, Angela Coxon, Julie M. Bailis

Molecular Cancer Therapeutics Oct 2021, 20 (10) 1977-1987; DOI: 10.1158/1535-7163.MCT-21-0236
A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Retter, Rabih Slim, Tara M. Young, William C. Olson, Gavin Thurston, Christopher Daly

Molecular Cancer Therapeutics Oct 2021, 20 (10) 1966-1976; DOI: 10.1158/1535-7163.MCT-21-0009
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
Michael S. Gordon, John Nemunaitis, Minal Barve, Zev A. Wainberg, Erika P. Hamilton, Ramesh K. Ramanathan, George W. Sledge, Huibin Yue, Susan E. Morgan-Lappe, Martha Blaney, Sreeneeranj Kasichayanula, Monica Motwani, Lan Wang, Louie Naumovski, John H. Strickler

Molecular Cancer Therapeutics Oct 2021, 20 (10) 1988-1995; DOI: 10.1158/1535-7163.MCT-20-0985
Imaging Reveals Importance of Shape and Flexibility for Glomerular Filtration of Biologics
Hanine Rafidi, Alberto Estevez, Gregory Z. Ferl, Danielle Mandikian, Shannon Stainton, Lauren Sermeño, Simon P. Williams, Amrita V. Kamath, James T. Koerber, C. Andrew Boswell

Molecular Cancer Therapeutics Oct 2021, 20 (10) 2008-2015; DOI: 10.1158/1535-7163.MCT-21-0116
Design of a Cytotoxic Neuroblastoma-Targeting Agent Using an Enzyme Acting on Polysialic Acid Fused to a Toxin
Timo A. Lehti, Maria I. Pajunen, Anne Jokilammi, Miikka Korja, Hauke Lilie, Kim Vettenranta, Jukka Finne

Molecular Cancer Therapeutics Oct 2021, 20 (10) 1996-2007; DOI: 10.1158/1535-7163.MCT-20-1031
Valency of HER2 Targeting Antibodies Influences Tumor Cell Internalization and Penetration
Madeleine K. Ramos, Danielle Mandikian, Lauren N. Sermeño, Anna King, Alecia T. Dent, Jason Ho, Sheila Ulufatu, T. Noelle Lombana, Christoph Spiess, Mary Ann T. Go, Shang-Fan Yu, Amrita V. Kamath, Gregory Z. Ferl, C. Andrew Boswell

Molecular Cancer Therapeutics Oct 2021, 20 (10) 1956-1965; DOI: 10.1158/1535-7163.MCT-20-1097
A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway
Melanie Wurm, Otmar Schaaf, Katharina Reutner, Rajkumar Ganesan, Sven Mostböck, Christina Pelster, Jark Böttcher, Bruna de Andrade Pereira, Christina Taubert, Isabella Alt, Garazi Serna, Aurelie Auguste, Kai B. Stadermann, Denis Delic, Fei Han, Jaume Capdevila, Paolo G. Nuciforo, Rachel Kroe-Barrett, Paul J. Adam, Anne B. Vogt, Irmgard Hofmann

Molecular Cancer Therapeutics Sep 2021, DOI: 10.1158/1535-7163.MCT-21-0107
Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models
Takuya Kato, Ryuhei Okada, Aki Furusawa, Fuyuki Inagaki, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Hiroshi Fukushima, Peter L. Choyke, Hisataka Kobayashi

Molecular Cancer Therapeutics Sep 2021, DOI: 10.1158/1535-7163.MCT-21-0470
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers
Samuel J. Klempner, Johanna C. Bendell, Victoria Meucci Villaflor, Laura LaNiel Tenner, Stacey M. Stein, James B. Rottman, Girish S. Naik, Cynthia A. Sirard, Michael H. Kagey, Marya F. Chaney, John H. Strickler

Molecular Cancer Therapeutics Sep 2021, DOI: 10.1158/1535-7163.MCT-21-0273

Main menu

User menu

Search

More articles from Large Molecule Therapeutics

Pages

Articles

Info for

About MCT